STING1 and neoplasm: The activation of the stimulator of interferon genes (STING) pathway is a cutting-edge strategy in tumor immunotherapy and has shown transformative potential in preclinical studies by inducing a type I interferon cascade and remodeling the tumor immune microenvironment.